Literature DB >> 27087648

Trans-Cinnamaldehyde, An Essential Oil in Cinnamon Powder, Ameliorates Cerebral Ischemia-Induced Brain Injury via Inhibition of Neuroinflammation Through Attenuation of iNOS, COX-2 Expression and NFκ-B Signaling Pathway.

Yuh-Fung Chen1,2, Yu-Wen Wang3, Wei-Shih Huang4,5, Ming-Ming Lee6, W Gibson Wood7, Yuk-Man Leung8, Huei-Yann Tsai9.   

Abstract

Trans-cinnamaldehyde (TCA), an essential oil in cinnamon powder, may have beneficial effects as a treatment for stroke which is the second leading cause of death worldwide. Post-ischemic inflammation induces neuronal cell damage after stroke, and activation of microglia, in particular, has been thought as the main contributor of proinflammatory and neurotoxic factors. The purpose of this study was to investigate the neuroprotective effects of TCA in an animal model of ischemia/reperfusion (I/R)-induced brain injury and the neuroprotective mechanism was verified in LPS-induced inflammation of BV-2 microglial cells. Our results showed that TCA (10-30 mg/kg, p.o.) significantly reduced the infarction area, neurological deficit score and decreased iNOS and COX-2 protein expression level in I/R-induced injury brain tissue. It inhibited 0.5 µg/ml LPS-induced NO production in BV-2 microglial cells without affecting cell viability, reduced protein expression of iNOS and COX-2, and attenuated inhibition of p53 protein. TCA also suppressed the effects of LPS-induced nuclear translocation of NF-κB p65 and p50 and increased cytosolic IκBα. It also reduced LPS-induced mRNA expression of iNOS, COX-2, and TNFα. We concluded that TCA has a potential neuroprotective effect to against the ischemic stroke, which may be via the inhibition of neuroinflammation through attenuating iNOS, COX-2 expression and NF-κB signaling pathway.

Entities:  

Keywords:  BV-2 microglia; Cerebral ischemia; NF-κB signaling pathway; Neuroinflammation; Trans-cinnamaldehyde

Mesh:

Substances:

Year:  2016        PMID: 27087648     DOI: 10.1007/s12017-016-8395-9

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  77 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  Toll-like receptors in the induction of the innate immune response.

Authors:  A Aderem; R J Ulevitch
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

Review 3.  The FEMA GRAS assessment of cinnamyl derivatives used as flavor ingredients.

Authors:  Timothy B Adams; Samuel M Cohen; John Doull; Victor J Feron; Jay I Goodman; Lawrence J Marnett; Ian C Munro; Philip S Portoghese; Robert L Smith; William J Waddell; Bernard M Wagner
Journal:  Food Chem Toxicol       Date:  2004-02       Impact factor: 6.023

Review 4.  NF-kappaB in neuronal plasticity and neurodegenerative disorders.

Authors:  M P Mattson; S Camandola
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

5.  C57BL/6 strain is most susceptible to cerebral ischemia following bilateral common carotid occlusion among seven mouse strains: selective neuronal death in the murine transient forebrain ischemia.

Authors:  G Yang; K Kitagawa; K Matsushita; T Mabuchi; Y Yagita; T Yanagihara; M Matsumoto
Journal:  Brain Res       Date:  1997-03-28       Impact factor: 3.252

6.  Activation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function.

Authors:  D W Moss; T E Bates
Journal:  Eur J Neurosci       Date:  2001-02       Impact factor: 3.386

Review 7.  Function and activation of NF-kappa B in the immune system.

Authors:  P A Baeuerle; T Henkel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

8.  Cognitive deficits after focal cerebral ischemia in mice.

Authors:  K Hattori; H Lee; P D Hurn; B J Crain; R J Traystman; A C DeVries
Journal:  Stroke       Date:  2000-08       Impact factor: 7.914

Review 9.  Inflammation as a therapeutic target in acute ischemic stroke treatment.

Authors:  Antonino Tuttolomondo; Riccardo Di Sciacca; Domenico Di Raimondo; Chiara Renda; Antonio Pinto; Giuseppe Licata
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

10.  Ocotea quixos Lam. essential oil: in vitro and in vivo investigation on its anti-inflammatory properties.

Authors:  Vigilio Ballabeni; Massimiliano Tognolini; Carmine Giorgio; Simona Bertoni; Renato Bruni; Elisabetta Barocelli
Journal:  Fitoterapia       Date:  2009-10-13       Impact factor: 2.882

View more
  28 in total

1.  The effects of Cinnamaldehyde on early brain injury and cerebral vasospasm following experimental subarachnoid hemorrhage in rabbits.

Authors:  Bora Gürer; Hayri Kertmen; Pınar Kuru Bektaşoğlu; Özden Çağlar Öztürk; Hüseyin Bozkurt; Abdullah Karakoç; Ata Türker Arıkök; Erhan Çelikoğlu
Journal:  Metab Brain Dis       Date:  2019-08-23       Impact factor: 3.584

Review 2.  Medicinal plants and their isolated phytochemicals for the management of chemotherapy-induced neuropathy: therapeutic targets and clinical perspective.

Authors:  Vahideh Oveissi; Mahboobe Ram; Roodabeh Bahramsoltani; Farnaz Ebrahimi; Roja Rahimi; Rozita Naseri; Tarun Belwal; Hari Prasad Devkota; Zahra Abbasabadi; Mohammad Hosein Farzaei
Journal:  Daru       Date:  2019-03-09       Impact factor: 3.117

3.  Orally Administered Cinnamon Extract Attenuates Cognitive and Neuronal Deficits Following Traumatic Brain Injury.

Authors:  Doaa Qubty; Vardit Rubovitch; Tali Benromano; Michael Ovadia; Chaim G Pick
Journal:  J Mol Neurosci       Date:  2020-09-08       Impact factor: 3.444

Review 4.  Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines.

Authors:  Matthew J Sharman; Giuseppe Verdile; Shanmugam Kirubakaran; Cristina Parenti; Ahilya Singh; Georgina Watt; Tim Karl; Dennis Chang; Chun Guang Li; Gerald Münch
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

5.  Trans-cinnamaldehyde protected PC12 cells against oxygen and glucose deprivation/reperfusion (OGD/R)-induced injury via anti-apoptosis and anti-oxidative stress.

Authors:  Xue Qi; Ru Zhou; Yue Liu; Jing Wang; Wan-Nian Zhang; Huan-Ran Tan; Yang Niu; Tao Sun; Yu-Xiang Li; Jian-Qiang Yu
Journal:  Mol Cell Biochem       Date:  2016-08-16       Impact factor: 3.396

6.  Trans-cinnamaldehyde Modulates Hippocampal Nrf2 Factor and Inhibits Amyloid Beta Aggregation in LPS-Induced Neuroinflammation Mouse Model.

Authors:  Doaa Abou El-Ezz; Ahmed Maher; Nada Sallam; Amany El-Brairy; Sanaa Kenawy
Journal:  Neurochem Res       Date:  2018-10-09       Impact factor: 3.996

7.  Anti-neuroinflammatory effects of galangin in LPS-stimulated BV-2 microglia through regulation of IL-1β production and the NF-κB signaling pathways.

Authors:  Mi Eun Kim; Pu Reum Park; Ju Yong Na; Inae Jung; Jun Hwi Cho; Jun Sik Lee
Journal:  Mol Cell Biochem       Date:  2018-07-11       Impact factor: 3.396

Review 8.  Inhalation Aromatherapy via Brain-Targeted Nasal Delivery: Natural Volatiles or Essential Oils on Mood Disorders.

Authors:  Jieqiong Cui; Meng Li; Yuanyuan Wei; Huayan Li; Xiying He; Qi Yang; Zhengkun Li; Jinfeng Duan; Zhao Wu; Qian Chen; Bojun Chen; Gang Li; Xi Ming; Lei Xiong; Dongdong Qin
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

9.  Inhibition of Lipopolysaccharide-Induced Inflammatory and Oxidative Responses by Trans-cinnamaldehyde in C2C12 Myoblasts.

Authors:  Cheol Park; Hyesook Lee; Suhyun Hong; Ilandarage Menu Neelaka Molagoda; Jin-Woo Jeong; Cheng-Yun Jin; Gi-Young Kim; Sung Hyun Choi; Sang Hoon Hong; Yung Hyun Choi
Journal:  Int J Med Sci       Date:  2021-04-23       Impact factor: 3.738

10.  The Extracts of Angelica sinensis and Cinnamomum cassia from Oriental Medicinal Foods Regulate Inflammatory and Autophagic Pathways against Neural Injury after Ischemic Stroke.

Authors:  Cheng Luo; Qi Chen; Bowen Liu; Shengpeng Wang; Hualin Yu; Xiaowei Guan; Yonghua Zhao; Yitao Wang
Journal:  Oxid Med Cell Longev       Date:  2021-06-26       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.